Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration
AssigneeBreye Therapeutics ApS
InventorsUlrik Mouritzen, Bradford Young
Life of this patent
Estimating the term…
Abstract
The use of Gap Junction-dependent cellular modulators in the treatment or prevention of age-related macular degeneration (AMD) is disclosed, and more particularly to their use for the treatment or prevention of dry AMD (d-AMD) and to prevent progression to wet or neovascular or advanced angiogenic AMD or geographic atrophy (GA).
Claims45
A compound of formula (I):
- or a pharmaceutically acceptable salt or hydrate thereof,
- for use in a method for treating or preventing age-related macular degeneration (AMD) in a human subject, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt or hydrate thereof.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the method is for the prevention of AMD in a human subject.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the method is for the prevention of progression of AMD in a human subject.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the method is for the prevention of progression of dry AMD to wet AMD in a human subject.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the method is for the prevention of progression of intermediate dry AMD to advanced forms of dry AMD in a human subject.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the AMD is characterized as early stage dry AMD.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the method is for the prevention of development of choroidal neovascularization in a human subject.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient has chronically high blood glucose levels including for a patient that is brought into glycaemic control.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient also has type 1 diabetes or type 2 diabetes.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient also has hypertension or chronically high blood pressure including for a patient that is brought into normal blood pressure control.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient has high cholesterol.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient also has diabetic retinopathy or diabetic macular edema.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient has retinal vein occlusion (RVO) eye disease.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient has glaucoma disease with or without pathological intraocular pressure.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient has uveitis or other forms of inflammatory eye disease.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the patient has or had drusen deposits or protein exudates in the eye.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound inhibits dysfunction of the RPE (retinal pigmented epithelium) or the outer blood retina barrier (oBRB).
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound inhibits stress induced dysfunction or the retinal or choroidal layers in the eye.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound inhibits the loss of photoreceptors in the eye.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound inhibits vascular leakage in the retina.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound improves fluid extraction from the retinal tissues via the retinal pigmented epithelium.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound inhibits death or loss of retinal endothelial cells, choroid endothelial cells, pericytes or epithelial cells.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound inhibits pathological hemichannel opening.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound inhibits pathological hemichannel ATP release.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the concentration of the administered compound, or pharmaceutically acceptable salt, hydrate or formulation thereof, such as an oral, systemic and sustained-release compound formulation, of about 50 nM to about 150 nM is reached in the microenvironment of the eye.
The compound for use in a method of treatment or prevention according to any one of the preceding claims, wherein the compound is administered to the patient once or twice daily.
Use of a compound of formula (I):
- or a pharmaceutically acceptable salt or hydrate thereof,
- for the preparation of a medicament for the treatment or prevention of age-related macular degeneration (AMD) in a human subject, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt or hydrate thereof.
A method of treating or preventing age-related macular degeneration (AMD) in a human subject, the method comprising administering to the human subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt or hydrate thereof;
- wherein the compound a compound of formula (I):
- or a pharmaceutically acceptable salt or hydrate thereof.
Dependencies are inferred from the claim text.